Navigation Links
Amira Pharmaceuticals Announces the Nomination of an Orally Available Pre-Clinical Candidate in a New LPA-Related Program, an Autotaxin Inhibitor
Date:12/15/2010

SAN DIEGO, Dec. 15, 2010 /PRNewswire/ -- Amira Pharmaceuticals, Inc. announced today that it has successfully identified a novel pre-clinical candidate for its newest lysophosphatidic acid (LPA)-related program, autotaxin.  Autotaxin is an enzyme upstream from LPA receptors and has been implicated in a number of diseases including rheumatoid arthritis, glioblastoma, lung, breast, ovarian and thyroid cancers.

"We are pleased to announce that we have identified an orally bioavailable and highly selective autotaxin inhibitor," said Peppi Prasit, Ph.D., Chief Scientific Officer.  "Previous published data implicates autotaxin as a potent stimulator of tumor cell motility.  Cells over expressing autotaxin result in amplified tumorigenesis and metastatic potential.  These observations when combined with our recent pre-clinical experiments, which demonstrated that an autotaxin-specific inhibitor can successfully inhibit tumor metastases, are quite exciting."

Bob Baltera, Chief Executive Officer added, "As we have stated before, we are committed to exploring the science and medicine related to the LPA pathway.  We believe there are numerous potential drug targets in this pathway, and our autotaxin inhibitor is the latest in our portfolio of LPA-related drug targets, which also includes our LPA1 receptor antagonist AM152 which is currently in phase 1 clinical trials.  While a great deal of work remains in advancing the autotaxin program to the clinic, we look forward to communicating our progress in 2011."

About Amira

Founded in 2005 and headquartered in San Diego, Amira Pharmaceuticals is a small molecule pharmaceutical company focused on the discovery and development of new drugs to treat inflammatory disease.  Our discovery team is building on unparalleled insights into bioactive lipid pathways and complex signaling processes controlling many conditions including asthma, chronic obstructive pulmonary disease, fibrotic diseases and cancer.  Amira combines the rigor of a big pharmaceutical company with the ingenuity and energy of a small company, creating an environment for efficient development of novel compounds and effective pre-clinical and clinical program decisions.  Amira has a partnership with GlaxoSmithKline for the development of FLAP (5-lipoxygenase activating protein) inhibitors in respiratory and cardiovascular disease.  For more information, visit www.amirapharm.com.


'/>"/>
SOURCE Amira Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Amira Pharmaceuticals Announces Initiation of Phase I Clinical Trial for AM152, A Novel LPA1 Antagonist
2. Amira Pharmaceuticals Announces IND Submission for Novel LPA1 Antagonist, AM152, for Potential Use in Fibrotic Diseases
3. Amira Pharmaceuticals Named One of Most Promising Biotech Companies by FierceBiotechs Annual Fierce 15
4. Visage Imaging Releases Amira 5.3
5. Amira Announces AM103 and AM803 Patent Grant in the United Kingdom
6. Amira Announces Second DP2 Antagonist Patent Grant in the United Kingdom
7. Anti-Fibrotic Data from Amira Pharmaceuticals LPA1 Receptor Antagonist Program Published in the British Journal of Pharmacology
8. Amira Pharmaceuticals Announces Efficacy of LPA1 Antagonist in a Preclinical Model of Scleroderma
9. Amira Pharmaceuticals Announces Initial Positive Phase 1 Clinical Data for AM461, A Back-Up to Amiras Lead DP2 Antagonist, AM211
10. Amira Pharmaceuticals Submits IND for Second DP2 Antagonist, AM461
11. Anthera Pharmaceuticals Selects the Merck BioManufacturing Network as Manufacturing Supplier for A-623, Antheras Investigational Novel Peptibody Agent
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/18/2017)... 18, 2017 Research and Markets has announced ... report to their offering. ... global arthroscopy devices market to grow at a CAGR of 6.35% ... Devices Market 2017-2021, has been prepared based on an in-depth market ... landscape and its growth prospects over the coming years. The report ...
(Date:4/18/2017)... DIEGO and BLOOMINGTON, Minn. ... Inc. (NASDAQ: IMMY ) ("Imprimis"), an ... Precision Lens ("Precision Lens"), today announced the signing ... the agreement, Precision Lens will deploy a dedicated ... select geographies in the U.S., primarily focused in ...
(Date:4/18/2017)... , April 18, 2017 Research and ... the United States Molecular Imaging Equipment and Radiopharmaceuticals Market, Forecast ... ... molecular imaging equipment revenues as well as growth in the ... will provide value to market participants that design and manufacture ...
Breaking Medicine Technology:
(Date:4/26/2017)... LOUIS (PRWEB) , ... April 26, 2017 , ... ... designed specifically to improve the profitability of ready-to-drink, high-protein beverages by helping beverage ... economic alternative to dairy proteins, providing direct cost savings as well as more ...
(Date:4/25/2017)... ... April 25, 2017 , ... Bellus ... that’s the first in a new class of photodynamic cosmetics (PDC). , Allumera® ... skin, visibly reduce outward signs of aging, and minimize the appearance of pores ...
(Date:4/25/2017)... ... April 25, 2017 , ... ... committed to raising awareness for Duchenne muscular dystrophy, and funding for Duchenne ... (cardiosphere-derived cells) Phase I/II HOPE clinical trial in Duchenne announced today. , ...
(Date:4/25/2017)... ... April 25, 2017 , ... A ... student test score performance for the 2015-16 school year across Wisconsin’s public schools, ... Though it highlights important patterns in student test score performance, the report’s limited ...
(Date:4/25/2017)... ... April 25, 2017 , ... Patients ... that achieves results in a fraction of the time as traditional braces – ... Significance Dental Specialists, now offers this revolutionary treatment with or without a referral. ...
Breaking Medicine News(10 mins):